Solid Biosciences Allegedly Failed to Disclose Risks of Lead Drug

A Solid Biosciences class action lawsuit has been filed on behalf of individuals who invested in the company after it allegedly made false and misleading statements, potentially violating federal laws. If you invested in Solid Biosciences Inc. between January 25, 2018 and March 14, 2018, or if you purchased shares before January 2018, you may be able to pursue a claim with the help of a securities fraud attorney.

For more information, contact Attorney Group today. Our consultations are free, confidential and without any obligation on your part. We can help answer your questions, and if you choose to pursue a claim we can connect you with an affiliated securities fraud attorney who can assist you throughout the legal process.

The deadline to file for lead plaintiff in this class action is May 29, 2018. Contact us for more information.Get Help Now.

FDA Places Clinical Hold on Solid Biosciences’ Lead Drug Candidate SGT-001

A class action lawsuit has been filed after Solid Biosciences Inc. allegedly violated federal securities laws when the company made false and misleading statements January 25, 2018 and March 14, 2018.

According to the complaint, plaintiffs claim that Solid Biosciences Inc. failed to disclose that Solid Biosciences’ lead drug candidate SGT-001 had a high likelihood of causing adverse events in patients and misled investors regarding the toxicity of SGT-001. As a result, the company’s statements in the Registration Statement regarding their business, operations, and prospects, were potentially false and/or misleading.

Solid Biosciences Inc. is a life science company devoted solely to solving Duchenne muscular dystrophy, an inherited disorder of progressive muscular weakness typically found in boys. Its lead drug candidate, known as SGT-001, is a form of gene therapy treatment in the clinical phase of development. On March 14, 2018, Solid Biosciences Inc. announced that it had received notification from the U.S. Food and Drug Administration (FDA) that its phase I/II clinical trial for SGT-001 had been placed on clinical hold.

Reported Impact on Solid Biosciences’ Stock Prices as a Result of the Company’s Alleged Fraud

A possible result of the alleged false and/or misleading statements made by Solid Biosciences Inc. includes the decline of Solid Biosciences’ stock (NASDAQ: SLDB) between March 13, 2018 and March 15, 2018. Shares of the company’s stock reportedly fell to as low as $8.95 per share in mid-March 2018.

Stock price per share on March 13, 2018:Stock price per share on March 15, 2018:Stock price decrease as a result of disclosures (percentage):
$28.81$8.9568.93 percent

How a Solid Biosciences Class Action Lawsuit Can Help

Individuals who invested money and purchased stock in Solid Biosciences Inc. January 25, 2018 and March 14, 2018, may be eligible to pursue damages and recover their losses through a Solid Biosciences class action lawsuit and are encouraged to seek the advice of an experienced securities fraud attorney to learn more about their rights and remedies.

The Time You Have to Pursue a Claim is Limited. Contact Us Today.

For more information, contact Attorney Group. You can fill out the form on this page or contact us by phone or email.

After you contact us, an attorney will follow up to answer questions that you might have. There is no cost or obligation to speak with us, and any information you provide will be kept confidential.

Please note that the law limits the time you have to pursue a claim or file a lawsuit for an injury. If you think you have a case, you should not delay taking action. Please also note, the deadline to file for lead plaintiff in this class action is May 29, 2018. You must file an application to be appointed lead plaintiff to this deadline in order to be considered by the court.